Vivani Medical VANI Biopharm Division — Other Nonoperating Income Expense

Other segment segments

Similar metrics at other companies

ANABBiopharma Company — Other Nonoperating Income Expense

-$1K+85.7%

PFEBiopharma — Other Nonoperating Income (Expense)

$116M+48.7%

ANABBiopharma Company — Nonoperating Income Expense

$2.33M-43.0%

MLTXOther Nonoperating Income

$3.21M-54.8%

ANNXInterest And Other Non Operating Income Expense

$1.91M-37.3%

AEIOther — Nonoperating Income Expense

-$2.54M+29.3%

Questions, answered.

What is Vivani Medical's biopharm division — other nonoperating income expense?

Vivani Medical (VANI) reported biopharm division — other nonoperating income expense of -$209K in Q1 2026.

How has Vivani Medical's biopharm division — other nonoperating income expense changed year-over-year?

Vivani Medical's biopharm division — other nonoperating income expense increased by 29.4% year-over-year, from -$296K to -$209K.

What is the long-term trend for Vivani Medical's biopharm division — other nonoperating income expense?

Over 2 years (2023 to 2025), Vivani Medical's biopharm division — other nonoperating income expense has grown at a -24.0% compound annual growth rate (CAGR), from $1.43M to $823K.

What does biopharm division — other nonoperating income expense mean?

Captures financial impacts outside of the segment's primary research and development operations, such as interest income, interest expense, or foreign exchange gains and losses. This metric provides a view of the segment's peripheral financial activities and their impact on the overall bottom line. It helps isolate core operational performance from incidental financial events.